Biomarkers-Aware Asymmetric Bibranch GAN With Adaptive Memory Batch Normalization for Prediction of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration.

The emergence of anti-vascular endothelial growth factor (anti-VEGF) therapy has revolutionized neovascular age-related macular degeneration (nAMD). Post-therapeutic optical coherence tomography (OCT) imaging facilitates the prediction of therapeutic response to anti-VEGF therapy for nAMD. Although the generative adversarial network (GAN) is a popular generative model for post-therapeutic OCT image generation, it is realistically challenging to gather sufficient pre- and post-therapeutic OCT image pairs, resulting in overfitting. Moreover, the available GAN-based methods ignore local details, such as the biomarkers that are essential for nAMD treatment. To address these issues, a Biomarkers-aware Asymmetric Bibranch GAN (BAABGAN) is proposed to efficiently generate post-therapeutic OCT images. Specifically, one branch is developed to learn prior knowledge with a high degree of transferability from large-scale data, termed the source branch. Then, the source branch transfer knowledge to another branch, which is trained on small-scale paired data, termed the target branch. To boost the transferability, a novel Adaptive Memory Batch Normalization (AMBN) is introduced in the source branch, which learns more effective global knowledge that is impervious to noise via memory mechanism. Also, a novel Adaptive Biomarkers-aware Attention (ABA) module is proposed to encode biomarkers information into latent features of target branches to learn finer local details of biomarkers. The proposed method outperforms traditional GAN models and can produce high-quality post-treatment OCT pictures with limited data sets, as shown by the results of experiments.